Susquehanna International Group, LLP Phathom Pharmaceuticals, Inc. Put Options Transaction History

Susquehanna International Group, LLP

  • $560 Billion
  • Q3 2024

Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$10.25 - $19.5 $121,975 - $232,050
-11,900 Reduced 39.4%
18,300 $330,000
Q2 2024

Aug 15, 2024
SELL
$8.97 - $12.05 $174,915 - $234,975
-19,500 Reduced 39.24%
30,200 $311,000
Q1 2024

May 07, 2024
BUY
$6.21 - $11.05 $308,637 - $549,185
49,700 New
49,700 $527,000
Q3 2023

Nov 14, 2023
SELL
$10.26 - $15.7 $80,028 - $122,460
-7,800 Reduced 22.94%
26,200 $271,000
Q2 2023

Aug 11, 2023
BUY
$7.28 - $14.32 $247,520 - $486,880
34,000 New
34,000 $486,000

Others Institutions Holding PHAT

# of Institutions
144
Shares Held
73.6M
Call Options Held
42.3K
Put Options Held
45.7K
View Full List

About Phathom Pharmaceuticals, Inc.

PHAT Quotes by TradingView
  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $294M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email